Literature DB >> 25697848

Complement in therapy and disease: Regulating the complement system with antibody-based therapeutics.

Joost P M Melis1, Kristin Strumane1, Sigrid R Ruuls1, Frank J Beurskens1, Janine Schuurman1, Paul W H I Parren2.   

Abstract

Complement is recognized as a key player in a wide range of normal as well as disease-related immune, developmental and homeostatic processes. Knowledge of complement components, structures, interactions, and cross-talk with other biological systems continues to grow and this leads to novel treatments for cancer, infectious, autoimmune- or age-related diseases as well as for preventing transplantation rejection. Antibodies are superbly suited to be developed into therapeutics with appropriate complement stimulatory or inhibitory activity. Here we review the design, development and future of antibody-based drugs that enhance or dampen the complement system.
Copyright © 2015 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Antibody; Antibody engineering; Cancer; Complement; Immunology; Therapy

Mesh：

Substances：

Year:  2015        PMID： 25697848     DOI： 10.1016/j.molimm.2015.01.028

Source DB:  PubMed          Journal:  Mol Immunol        ISSN： 0161-5890            Impact factor:   4.407


  54 in total

1.  Increased complements and high-sensitivity C-reactive protein predict heart failure in acute myocardial infarction.

Authors:  Danni Liu; Xin Qi; Qi Li; Wenjun Jia; Liping Wei; Anan Huang; Keqiang Liu; Zongjin Li
Journal:  Biomed Rep       Date:  2016-10-27

Review 2.  Antibodies Against Complement Components: Relevance for the Antiphospholipid Syndrome-Biomarkers of the Disease and Biopharmaceuticals.

Authors:  Mirjana Bećarević
Journal:  Curr Rheumatol Rep       Date:  2017-07       Impact factor: 4.592

3.  Structural Insights into Reovirus σ1 Interactions with Two Neutralizing Antibodies.

Authors:  Melanie H Dietrich; Kristen M Ogden; Sarah P Katen; Kerstin Reiss; Danica M Sutherland; Robert H Carnahan; Matthew Goff; Tracy Cooper; Terence S Dermody; Thilo Stehle
Journal:  J Virol       Date:  2017-01-31       Impact factor: 5.103

4.  Antibody Engineering & Therapeutics, the annual meeting of The Antibody Society December 7-10, 2015, San Diego, CA, USA.

Authors:  Matthias Pauthner; Jenny Yeung; Chris Ullman; Joost Bakker; Thierry Wurch; Janice M Reichert; Fridtjof Lund-Johansen; Andrew R M Bradbury; Paul J Carter; Joost P M Melis
Journal:  MAbs       Date:  2016       Impact factor: 5.857

Review 5.  New milestones ahead in complement-targeted therapy.

Authors:  Daniel Ricklin; John D Lambris
Journal:  Semin Immunol       Date:  2016-06-16       Impact factor: 11.130

6.  Antibodies That Efficiently Form Hexamers upon Antigen Binding Can Induce Complement-Dependent Cytotoxicity under Complement-Limiting Conditions.

Authors:  Erika M Cook; Margaret A Lindorfer; Hilma van der Horst; Simone Oostindie; Frank J Beurskens; Janine Schuurman; Clive S Zent; Richard Burack; Paul W H I Parren; Ronald P Taylor
Journal:  J Immunol       Date:  2016-07-29       Impact factor: 5.422

7.  A potent complement factor C3-specific nanobody inhibiting multiple functions in the alternative pathway of human and murine complement.

Authors:  Rasmus K Jensen; Rasmus Pihl; Trine A F Gadeberg; Jan K Jensen; Kasper R Andersen; Steffen Thiel; Nick S Laursen; Gregers R Andersen
Journal:  J Biol Chem       Date:  2018-03-01       Impact factor: 5.157

Review 8.  Sepsis-induced myocardial dysfunction: the role of mitochondrial dysfunction.

Authors:  Hang Yang; Zhaocai Zhang
Journal:  Inflamm Res       Date:  2021-03-08       Impact factor: 4.575

9.  Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy.

Authors:  Martin Skarzynski; Carsten U Niemann; Yuh Shan Lee; Sabrina Martyr; Irina Maric; Dalia Salem; Maryalice Stetler-Stevenson; Gerald E Marti; Katherine R Calvo; Constance Yuan; Janet Valdez; Susan Soto; Mohammed Z H Farooqui; Sarah E M Herman; Adrian Wiestner
Journal:  Clin Cancer Res       Date:  2015-08-17       Impact factor: 12.531

Review 10.  Biologics for the treatment of autoimmune renal diseases.

Authors:  Stephen R Holdsworth; Poh-Yi Gan; A Richard Kitching
Journal:  Nat Rev Nephrol       Date:  2016-03-07       Impact factor: 28.314
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.